Do multiple nuclear factor kappa B activation mechanisms explain its varied effects in the heart?

Ochsner Journal

Volumn 13, Issue 1, 2013, Pages 157-165

  Kumar, Rajesh ^a   Yong, Qian Chen ^a   Thomas, Candice M ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Cytokines; Diabetes mellitus; Heart; NF kappa B; Reninangiotensin system

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PRALNACASAN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; HEART; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; ISCHEMIC CARDIOMYOPATHY; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

EID: 84875147195     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-1070.
2. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007 Jun 26;115(25):3213-3223.
3. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1257-1266.
4. Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS. Angiotensin II induces gene transcription through cell-typedependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem. 2000 Sep;212(1-2):155-169.
5. Brasier AR. The NF-kappaB regulatory network. Cardiovasc Toxicol. 2006;6(2):111-130.
6. Gupta S, Young D, Maitra RK, et al. Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol. 2008 Jan 18;375(3):637-649. Epub 2007 Oct 10.
7. Li Q, Guo Y, Tan W, et al. Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway. Circulation. 2007 Oct 2;116(14):1577-1584. Epub 2007 Sep 4.
8. Wu S, Yin R, Ernest R, et al. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res. 2009 Oct 1;84(1):119-126. Epub 2009 Jun 1.
9. Young D, Popovic ZB, Jones WK, Gupta S. Blockade of NFkappaB using IkappaB alpha dominant-negative mice ameliorates cardiac hypertrophy in myotrophin-overexpressed transgenic mice. J Mol Biol. 2008 Sep 5;381(3):559-568. Epub 2008 Jun 5.
10. Freund C, Schmidt-Ullrich R, Baurand A, et al. Requirement of nuclear factor-kappaB in angiotensin II-and isoproterenolinduced cardiac hypertrophy in vivo. Circulation. 2005 May 10; 111(18):2319-2325. Epub 2005 May 3.
11. Zelarayan L, Renger A, Noack C, et al. NF-kappaB activation is required for adaptive cardiac hypertrophy. Cardiovasc Res. 2009 Dec 1;84(3):416-424. Epub 2009 Jul 20.
12. Kratsios P, Huth M, Temmerman L, et al. Antioxidant amelioration of dilated cardiomyopathy caused by conditional deletion of NEMO/IKKgamma in cardiomyocytes. Circ Res. 2010 Jan 8; 106(1):133-144. Epub 2009 Oct 22.
13. Hamid T, Guo SZ, Kingery JR, et al. Cardiomyocyte NF-jB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res. 2011 Jan 1; 89(1):129-138. Epub 2010 Aug 25.
14. Sorriento D, Santulli G, Fusco A, et al. Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NFkappaB-dependent hypertrophic gene expression. Hypertension. 2010 Oct;56(4):696-704. Epub 2010 Jul 26.
15. Satou R, Miyata K, Katsurada A, Navar LG, Kobori H. Tumor necrosis factor-a suppresses angiotensinogen expression through formation of a p50/p50 homodimer in human renal proximal tubular cells. Am J Physiol Cell Physiol. 2010 Oct; 299(4):C750-C759. Epub 2010 Jun 30.
16. Cui R, Tieu B, Recinos A, Tilton RG, Brasier AR. RhoA mediates angiotensin II-induced phospho-Ser536 nuclear factor kappaB/RelA subunit exchange on the interleukin-6 promoter in VSMCs. Circ Res. 2006 Sep 29;99(7):723-730. Epub 2006 Sep 7.
17. Ea CK, Baltimore D. Regulation of NF-kappaB activity through lysine monomethylation of p65. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):18972-18977. Epub 2009 Oct 28.
18. Li Y, Reddy MA, Miao F, et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaBdependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem. 2008 Sep 26;283(39):26771-26781. Epub 2008 Jul 23.
19. Zhang LX, Zhao Y, Cheng G, et al. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. Am J Physiol Heart Circ Physiol. 2010 Jun;298(6): H2154-H2163. Epub 2010 Apr 9.
20. Birbach A, Gold P, Binder BR, et al. Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem. 2002 Mar 29;277(13):10842-10851. Epub 2002 Jan 18.
21. Manea A, Manea SA, Gafencu AV, Raicu M. Regulation of NADPH oxidase subunit p22(phox) by NF-kB in human aortic smooth muscle cells. Arch Physiol Biochem. 2007 Oct-Dec;113(4-5): 163-172.
22. Hingtgen SD, Li Z, Kutschke W, Tian X, Sharma RV, Davisson RL. Superoxide scavenging and Akt inhibition in myocardium ameliorate pressure overload-induced NF-jB activation and cardiac hypertrophy. Physiol Genomics. 2010 Apr 1;41(2):127-136. Epub 2010 Jan 26.
23. Seymour EM, Bennink MR, Watts SW, Bolling SF. Whole grape intake impacts cardiac peroxisome proliferator-activated receptor and nuclear factor kappaB activity and cytokine expression in rats with diastolic dysfunction. Hypertension. 2010 May;55(5):1179-1185. Epub 2010 Mar 15.
24. Miguel-Carrasco JL, Zambrano S, Blanca AJ, Mate A, Vázquez CM. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm (Lond). 2010 May 12;7:21.
25. Timmers L, van Keulen JK, Hoefer IE, et al. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ Res. 2009 Mar 13;104(5):699-706. Epub 2009 Jan 24.
26. Frantz S, Hu K, Bayer B, et al. Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J. 2006 Sep;20(11):1918-1920. Epub 2006 Jul 12.
27. Santos DG, Resende MF, Mill JG, et al. Nuclear Factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure. BMC Med Genet. 2010 Jun 9;11:89.
28. Gaspar-Pereira S, Fullard N, Townsend PA, et al. The NF-jB subunit c-Rel stimulates cardiac hypertrophy and fibrosis. Am J Pathol. 2012 Mar;180(3):929-939. Epub 2011 Dec 30.
29. Leychenko A, Konorev E, Jijiwa M, Matter ML. Stretch-induced hypertrophy activates NFkB-mediated VEGF secretion in adult cardiomyocytes. PLoS One. 2011;6(12):e29055. Epub 2011 Dec 13.
30. Liu Q, Chen Y, Auger-Messier M, Molkentin JD. Interaction between NFjB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res. 2012 Apr 13;110(8):1077-1086. Epub 2012 Mar 8.
31. Wilkins BJ, Dai YS, Bueno OF, et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004 Jan 9;94(1):110-118. Epub 2003 Dec 1.
32. Islam KN, Koch WJ. Involvement of nuclear factor jB (NF-jB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression. J Biol Chem. 2012 Apr 13; 287(16):12771-12778. Epub 2012 Mar 2.
33. Brown M, McGuinness M, Wright T, et al. Cardiac-specific blockade of NF-kappaB in cardiac pathophysiology: differences between acute and chronic stimuli in vivo. Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H466-H476. Epub 2005 Feb 4.
34. Kumar S, Wei C, Thomas CM, et al. Cardiac-specific genetic inhibition of nuclear factor-jB prevents right ventricular hypertrophy induced by monocrotaline. Am J Physiol Heart Circ Physiol. 2012 Apr 15;302(8):H1655-H1666. Epub 2012 Jan 13.
35. Maier HJ, Schips TG, Wietelmann A, et al. Cardiomyocytespecific IjB kinase (IKK)/NF-jB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11794-11799. Epub 2012 Jul 2.
36. Lu H, Raptis M, Black E, Stan M, Amar S, Graves DT. Influence of diabetes on the exacerbation of an inflammatory response in cardiovascular tissue. Endocrinology. 2004 Nov;145(11):4934-4939. Epub 2004 Jul 29.
37. Mariappan N, Elks CM, Sriramula S, et al. NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res. 2010 Feb 1; 85(3):473-483. Epub 2009 Sep 3.
38. Ko HJ, Zhang Z, Jung DY, et al. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes. 2009 Nov; 58(11):2536-2546. Epub 2009 Aug 18.
39. Zhang M, Kho AL, Anilkumar N, et al. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation. 2006 Mar 7;113(9):1235-1243. Epub 2006 Feb 27.
40. Westermann D, Rutschow S, Van Linthout S, et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia. 2006 Oct;49(10):2507-2513. Epub 2006 Aug 26.
41. Westermann D, Van Linthout S, Dhayat S, et al. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes. 2007 Jul;56(7):1834-1841. Epub 2007 May 1.
42. Westermann D, Rutschow S, Jäger S, et al. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes. 2007 Mar;56(3):641-646.
43. Van Linthout S, Riad A, Dhayat N, et al. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia. 2007 Sep;50(9):1977-1986. Epub 2007 Jun 23.
44. Giunti S, Calkin AC, Forbes JM, et al. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am J Physiol Renal Physiol. 2010 Sep;299(3):F528-F535. Epub 2010 Jun 16.
45. Westermann D, Van Linthout S, Dhayat S, et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol. 2007 Nov;102(6):500-507. Epub 2007 Oct 5.
46. Chen S, Khan ZA, Cukiernik M, Chakrabarti S. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab. 2003 Jun;284(6):E1089-E1097. Epub 2003 Feb 11.
47. Min W, Bin ZW, Quan ZB, Hui ZJ, Sheng FG. The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats. Cardiovasc Diabetol. 2009 Feb 11;8:8.
48. Tsai KH, Wang WJ, Lin CW, et al. NADPH oxidase-derived superoxide anion-induced apoptosis is mediated via the JNKdependent activation of NF-jB in cardiomyocytes exposed to high glucose. J Cell Physiol. 2012 Apr;227(4):1347-1357.
49. Mustapha S, Kirshner A, De Moissac D, Kirshenbaum LA. A direct requirement of nuclear factor-kappa B for suppression of apoptosis in ventricular myocytes. Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H939-H945.
50. Palomer X, Alvarez-Guardia D, Rodríguez-Calvo R, et al. TNFalpha reduces PGC-1alpha expression through NF-kappaB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc Res. 2009 Mar 1;81(4):703-712. Epub 2008 Nov 27.
51. Wang Y, Feng W, Xue W, et al. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes. 2009 Jun;58(6):1391-1402. Epub 2009 Mar 26.
52. Haudek SB, Bryant DD, Giroir BP. Differential regulation of myocardial NF kappa B following acute or chronic TNF-alpha exposure. J Mol Cell Cardiol. 2001 Jun;33(6):1263-1271.
53. Rouet-Benzineb P, Gontero B, Dreyfus P, Lafuma C. Angiotensin II induces nuclear factor-kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol. 2000 Oct;32(10):1767-1778.
54. Kalra D, Sivasubramanian N, Mann DL. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation. 2002 May 7;105(18):2198-2205.
55. Tadevosyan A, Maguy A, Villeneuve LR, et al. Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J Biol Chem. 2010 Jul 16;285(29):22338-22349. Epub 2010 May 12.
56. Kumar R, Thomas CM, Yong QC, Chen W, Baker KM. The intracrine renin-angiotensin system. Clin Sci (Lond). 2012 Sep; 123(5):273-284.
57. Cook JL, Re RN. Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model. Am J Physiol Regul Integr Comp Physiol. 2012 Mar 1;302(5):R482-R493. Epub 2011 Dec 14.
58. Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol. 2012 Mar 1;302(5):R518-R530. Epub 2011 Dec 14.
59. Ellis B, Li XC, Miguel-Qin E, Gu V, Zhuo JL. Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney. Am J Physiol Regul Integr Comp Physiol. 2012 Mar 1;302(5):R494-R509. Epub 2011 Dec 14.
60. Shang LL, Sanyal S, Pfahnl AE, et al. NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol. 2008 Jan;294(1):C372-C379. Epub 2007 Nov 21.
61. Muller DN, Dechend R, Mervaala EM, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000 Jan;35(1 Pt 2):193-201.